We presented evidence that in AML patients, TET2 is specifically involved in the DNA demethylation near TFBS of RUNX1 and CEBPA, particularly in demethylation of CpG TL—functional CpG positions in which methylation is a marker of the gene expression nearby. Here, TET2 is linked to acute myeloid leukemia.